family with sequence similarity 24 member AGenealiases: []
Q-omics provides the consensus-scored FAM24A profile across patient tissues and cancer cell-line models. FAM24A expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, FAM24A is differentially expressed in 2, with the highest sampling consensus in HNSC. Additionally, FAM24A RNA expression shows 5,507 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCS, HNSC, and STAD as cancer lineages where FAM24A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM24A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM24A survival associations across molecular data types. FAM24A RNA expression shows survival associations in the most cancer types (9), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM24A RNA expression–survival associations across cancer types. High FAM24A expression shows unfavorable associations in THYM, LUAD, HNSC, MESO and STAD, but favorable associations in UCS. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .015). Together, the overview and detailed table identify UCS as the clearest survival context for FAM24A RNA expression.
This table summarizes FAM24A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM24A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM24A shows higher tumor expression in HNSC and BRCA. The HNSC box plot shows higher FAM24A RNA expression in tumor versus normal tissue (log2 FC = +0.024, t-test p = .016).
This table shows molecular features associated with FAM24A in patient tissues and cancer cell lines. In patient samples, FAM24A shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM24A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
